NervGen Pharma Corp. (NGEN) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$1.36

From 52W high−77.39%

Volume106922.00

Market cap$145.28M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$1.36

From 52W high

−77.39%

Volume

106922.00

Market cap

$145.28M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−10.0x

P/E (TTM)

—

RSI (14)

25.7

MomentumView details →

1D Return

+2.27%

YTD Return

−76.52%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−10.0x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

11.8x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−390.39%

ROA (TTM)

−74.79%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

−69.44%

EBITDA YoY

+49.35%

MomentumView details →

1D Return

+2.27%

YTD Return

−76.52%

1Y Return

—

RSI (14)

25.7

vs 50D SMA

−28.97%

vs 200D SMA

−52.73%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

1.23x

Quick Ratio

1.23x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.37

EPS Surprise

−510.76%

Beats (12Q)

1/12

Next Q EPS Est

−$0.09

Avg Surprise (4Q)

−198.51%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−67.56M

Op. CF (TTM)

−29.60M

Next earningsNov 12, 2026 →

Latest newsMore news →

NervGen announced it will restate its audited annual financial statements for the year ended December 31, 2025 and its unaudited interim financial statements for the quarter ended June 30, 2026 to recognize non-cash accounting adjustments.40d ago

Similar companies

MacroGenics, Inc.MGNX Avidity Biosciences, Inc.RNA Protara Therapeutics, Inc.TARA Veraxa Biotech Holding AGVRXA Compass Therapeutics, Inc.CMPX Cue Biopharma, Inc.CUE Find similar companies →

Latest newsMore news →

NervGen announced it will restate its audited annual financial statements for the year ended December 31, 2025 and its unaudited interim financial statements for the quarter ended June 30, 2026 to recognize non-cash accounting adjustments.40d ago